CelLBxHealth lands contract with Swiss biotech for clinical study

Impact · against what's priced in

CLBX provides a concrete roadmap for growth with 2027 revenue targets and a new strategic entry into the radiopharmaceutical market. HE1 and ZPHR receive modest positive updates regarding funding and landholdings, respectively.

CLBX+0.60

No priced-in read yet

In context

The company provided a specific 2027 revenue target of £3-4 million, supported by a 200% YoY increase in Q3 new business and a new strategic entry into the radiopharmaceutical clinical study market.

Read from the article alone

• clinical studyNew
• biotech▲12%
• CLBX
• HE1
• ZPHR
• cancer research
• diagnostics
• pharma